サマリー

主なブランドインスリン製品の特許が今後数年で切れ始めるため、バイオシミラーインスリンがインスリン市場に参入する可能性があります。バイオシミラーインスリンは、糖尿病の治療費を削減し、インスリン治療へのアクセスを向上させ、糖尿病患者が利用できるインスリンのブランド数を拡大する可能性があります。

市場分析とインサイトインスリンバイオシミラーの世界市場
インスリンバイオシミラーの世界市場は、2020年に100万米ドルとなっています。2021-2027年の間にCAGR％で成長し、2027年末には市場規模が100万米ドルに達する見込みです。

インスリンバイオシミラーの世界市場規模とセグメント
インスリンバイオシミラー市場は、タイプ別、アプリケーション別に分類されています。世界のインスリンバイオシミラー市場に参加するプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年までのタイプ別、アプリケーション別の売上高、収益、予測に焦点を当てています。

タイプ別セグメント
速効性バイオシミラー
ロングアクティングバイオシミラー(Long-Acting Biosimilars)
プレミックスバイオシミラー(Premixed Biosimilars)

用途別セグメント
I型糖尿病
II型糖尿病

会社別
サノフィS.A.
ベーリンガーインゲルハイム（Boehringer Ingelheim
Eli Lilly & Co.
ノボ ノルディスク A/S
バイオコン
ジェロファム
ヴォックハルト
ガン＆リー・ファーマシューティカルズ
ザ・ユナイテッド・ラボラトリーズ・インターナショナル
通化東宝製薬

地域別
北アメリカ
アメリカ
カナダ
ヨーロッパ
ドイツ
フランス
U.K.
イタリア
ロシア
アジアパシフィック
中国
日本
韓国
インド
オーストラリア
中国 台湾
インドネシア
タイ
マレーシア
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
コロンビア
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

ページTOPに戻る

目次

1 Study Coverage
1.1 Insulin Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Insulin Biosimilars Market Size Growth Rate by Type
1.2.2 Rapid-Acting Biosimilars
1.2.3 Long-Acting Biosimilars
1.2.4 Premixed Biosimilars
1.3 Market by Application
1.3.1 Global Insulin Biosimilars Market Size Growth Rate by Application
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Insulin Biosimilars Sales Estimates and Forecasts 2016-2027
2.2 Global Insulin Biosimilars Revenue Estimates and Forecasts 2016-2027
2.3 Global Insulin Biosimilars Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Insulin Biosimilars Regions by Sales
2.4.1 Global Top Insulin Biosimilars Regions by Sales (2016-2021)
2.4.2 Global Top Insulin Biosimilars Regions by Sales (2022-2027)
2.5 Global Top Insulin Biosimilars Regions by Revenue
2.5.1 Global Top Insulin Biosimilars Regions by Revenue (2016-2021)
2.5.2 Global Top Insulin Biosimilars Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Insulin Biosimilars Sales by Manufacturers
3.1.1 Global Top Insulin Biosimilars Manufacturers by Sales (2016-2021)
3.1.2 Global Top Insulin Biosimilars Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Insulin Biosimilars Sales in 2020
3.2 Global Insulin Biosimilars Revenue by Manufacturers
3.2.1 Global Top Insulin Biosimilars Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Insulin Biosimilars Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Insulin Biosimilars Revenue in 2020
3.3 Global Insulin Biosimilars Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Insulin Biosimilars Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Insulin Biosimilars Sales by Type
4.1.1 Global Insulin Biosimilars Historical Sales by Type (2016-2021)
4.1.2 Global Insulin Biosimilars Forecasted Sales by Type (2022-2027)
4.1.3 Global Insulin Biosimilars Sales Market Share by Type (2016-2027)
4.2 Global Insulin Biosimilars Revenue by Type
4.2.1 Global Insulin Biosimilars Historical Revenue by Type (2016-2021)
4.2.2 Global Insulin Biosimilars Forecasted Revenue by Type (2022-2027)
4.2.3 Global Insulin Biosimilars Revenue Market Share by Type (2016-2027)
4.3 Global Insulin Biosimilars Price by Type
4.3.1 Global Insulin Biosimilars Price by Type (2016-2021)
4.3.2 Global Insulin Biosimilars Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Insulin Biosimilars Sales by Application
5.1.1 Global Insulin Biosimilars Historical Sales by Application (2016-2021)
5.1.2 Global Insulin Biosimilars Forecasted Sales by Application (2022-2027)
5.1.3 Global Insulin Biosimilars Sales Market Share by Application (2016-2027)
5.2 Global Insulin Biosimilars Revenue by Application
5.2.1 Global Insulin Biosimilars Historical Revenue by Application (2016-2021)
5.2.2 Global Insulin Biosimilars Forecasted Revenue by Application (2022-2027)
5.2.3 Global Insulin Biosimilars Revenue Market Share by Application (2016-2027)
5.3 Global Insulin Biosimilars Price by Application
5.3.1 Global Insulin Biosimilars Price by Application (2016-2021)
5.3.2 Global Insulin Biosimilars Price Forecast by Application (2022-2027)

6 North America
6.1 North America Insulin Biosimilars Market Size by Type
6.1.1 North America Insulin Biosimilars Sales by Type (2016-2027)
6.1.2 North America Insulin Biosimilars Revenue by Type (2016-2027)
6.2 North America Insulin Biosimilars Market Size by Application
6.2.1 North America Insulin Biosimilars Sales by Application (2016-2027)
6.2.2 North America Insulin Biosimilars Revenue by Application (2016-2027)
6.3 North America Insulin Biosimilars Market Size by Country
6.3.1 North America Insulin Biosimilars Sales by Country (2016-2027)
6.3.2 North America Insulin Biosimilars Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Insulin Biosimilars Market Size by Type
7.1.1 Europe Insulin Biosimilars Sales by Type (2016-2027)
7.1.2 Europe Insulin Biosimilars Revenue by Type (2016-2027)
7.2 Europe Insulin Biosimilars Market Size by Application
7.2.1 Europe Insulin Biosimilars Sales by Application (2016-2027)
7.2.2 Europe Insulin Biosimilars Revenue by Application (2016-2027)
7.3 Europe Insulin Biosimilars Market Size by Country
7.3.1 Europe Insulin Biosimilars Sales by Country (2016-2027)
7.3.2 Europe Insulin Biosimilars Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Insulin Biosimilars Market Size by Type
8.1.1 Asia Pacific Insulin Biosimilars Sales by Type (2016-2027)
8.1.2 Asia Pacific Insulin Biosimilars Revenue by Type (2016-2027)
8.2 Asia Pacific Insulin Biosimilars Market Size by Application
8.2.1 Asia Pacific Insulin Biosimilars Sales by Application (2016-2027)
8.2.2 Asia Pacific Insulin Biosimilars Revenue by Application (2016-2027)
8.3 Asia Pacific Insulin Biosimilars Market Size by Region
8.3.1 Asia Pacific Insulin Biosimilars Sales by Region (2016-2027)
8.3.2 Asia Pacific Insulin Biosimilars Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Insulin Biosimilars Market Size by Type
9.1.1 Latin America Insulin Biosimilars Sales by Type (2016-2027)
9.1.2 Latin America Insulin Biosimilars Revenue by Type (2016-2027)
9.2 Latin America Insulin Biosimilars Market Size by Application
9.2.1 Latin America Insulin Biosimilars Sales by Application (2016-2027)
9.2.2 Latin America Insulin Biosimilars Revenue by Application (2016-2027)
9.3 Latin America Insulin Biosimilars Market Size by Country
9.3.1 Latin America Insulin Biosimilars Sales by Country (2016-2027)
9.3.2 Latin America Insulin Biosimilars Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia

10 Middle East and Africa
10.1 Middle East and Africa Insulin Biosimilars Market Size by Type
10.1.1 Middle East and Africa Insulin Biosimilars Sales by Type (2016-2027)
10.1.2 Middle East and Africa Insulin Biosimilars Revenue by Type (2016-2027)
10.2 Middle East and Africa Insulin Biosimilars Market Size by Application
10.2.1 Middle East and Africa Insulin Biosimilars Sales by Application (2016-2027)
10.2.2 Middle East and Africa Insulin Biosimilars Revenue by Application (2016-2027)
10.3 Middle East and Africa Insulin Biosimilars Market Size by Country
10.3.1 Middle East and Africa Insulin Biosimilars Sales by Country (2016-2027)
10.3.2 Middle East and Africa Insulin Biosimilars Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Sanofi S.A.
11.1.1 Sanofi S.A. Corporation Information
11.1.2 Sanofi S.A. Overview
11.1.3 Sanofi S.A. Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Sanofi S.A. Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi S.A. Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Corporation Information
11.2.2 Boehringer Ingelheim Overview
11.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Boehringer Ingelheim Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Boehringer Ingelheim Recent Developments
11.3 Eli Lilly & Co.
11.3.1 Eli Lilly & Co. Corporation Information
11.3.2 Eli Lilly & Co. Overview
11.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Eli Lilly & Co. Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Eli Lilly & Co. Recent Developments
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Corporation Information
11.4.2 Novo Nordisk A/S Overview
11.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Novo Nordisk A/S Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novo Nordisk A/S Recent Developments
11.5 Biocon
11.5.1 Biocon Corporation Information
11.5.2 Biocon Overview
11.5.3 Biocon Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Biocon Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biocon Recent Developments
11.6 Geropharm
11.6.1 Geropharm Corporation Information
11.6.2 Geropharm Overview
11.6.3 Geropharm Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Geropharm Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Geropharm Recent Developments
11.7 Wockhardt
11.7.1 Wockhardt Corporation Information
11.7.2 Wockhardt Overview
11.7.3 Wockhardt Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Wockhardt Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Wockhardt Recent Developments
11.8 Gan&Lee Pharmaceuticals
11.8.1 Gan&Lee Pharmaceuticals Corporation Information
11.8.2 Gan&Lee Pharmaceuticals Overview
11.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Gan&Lee Pharmaceuticals Recent Developments
11.9 The United Laboratories International
11.9.1 The United Laboratories International Corporation Information
11.9.2 The United Laboratories International Overview
11.9.3 The United Laboratories International Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 The United Laboratories International Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 The United Laboratories International Recent Developments
11.10 Tonghua Dongbao Pharmaceutical
11.10.1 Tonghua Dongbao Pharmaceutical Corporation Information
11.10.2 Tonghua Dongbao Pharmaceutical Overview
11.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Tonghua Dongbao Pharmaceutical Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Insulin Biosimilars Value Chain Analysis
12.2 Insulin Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Insulin Biosimilars Production Mode & Process
12.4 Insulin Biosimilars Sales and Marketing
12.4.1 Insulin Biosimilars Sales Channels
12.4.2 Insulin Biosimilars Distributors
12.5 Insulin Biosimilars Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Insulin Biosimilars Industry Trends
13.2 Insulin Biosimilars Market Drivers
13.3 Insulin Biosimilars Market Challenges
13.4 Insulin Biosimilars Market Restraints

14 Key Findings in The Global Insulin Biosimilars Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer